CPI-203 CAS:1446144-04-2, a primary amide analog of (+)-JQ1, is a potent, selective and competitive small molecule inhibitor of BET bromodomain with an average GI50 value of 0.23μM in MCL cell lines . It exhibits excellent bioavailability when administered orally or intraperitoneally. CPI-203 downregulates Myc expression, causes G1 cell cycle arrest and attenuates cell proliferation in human pancreatic neuroendocrine tumors. As an inhibitor of BET protein, CPI-203 inhibits BRD4 in vitro and in cells. It inhibits specific Ser2 phosphorylation of endogenous BRD4 and exogenous mutant BRD4 (BRD4 FEE-AAA) in vivo, thereby blocking BRD4 recruitment to chromatin.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
![N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazolin-4-amine](https://e1752fbe.rocketcdn.me/wp-content/uploads/AP14270-CAS-231278-20-9-1-e1686064939791.png)
![l-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-lHpyrazolo [3,4-d]pyrimidin-l-yl]-l-piperidinyl]-2-propyn-l-one](https://e1752fbe.rocketcdn.me/wp-content/uploads/AP14272-CAS-936563-91-6-1-e1686054563587.png)